Search

Displaying results 3461 - 3470 of 9702 in total
  1. Drug

    Eptotermin alfa

    go.drugbank.com/drugs/DB11631
    ApprovedWithdrawn

    A bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis.

  2. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release … Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine

  3. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … BMP-2 is a potent osteoinductive protein that plays a critical role in the differentiation of osteoprogenitor cells into osteoblasts, thus promoting bone and cartilage formation [A31952].

  4. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  6. Drug

    Trigonellamide

    go.drugbank.com/drugs/DB11710
    Investigational

    Trigonellamide is under investigation in clinical trial NCT01930240 (The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers).

  7. Drug

    Depatuxizumab mafodotin

    go.drugbank.com/drugs/DB11731
    Investigational

    Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.

  8. Drug

    Galactose

    go.drugbank.com/drugs/DB11735
    ApprovedInvestigationalWithdrawn

    As a naturally occurring sugar, it may be found in a number dairy products. Even then, however, it is not generally used as a sweetener considering it is only about 30% as sweet as sucrose. … Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body, galactose is involved as an ingredient in some commonly used vaccines and non-prescription products

  9. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

  10. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and...